

# **VNM Update- HOLD**

February 21, 2023

**ACBS Research Department** Tel: (+84) (8) 3823 4159 (ext: 354) www.acbs.com.vn Bloomberg: ACBS <GO> 1



## Ms. Chi Luong

(+84 28) 7300 7000 - Ext: 1042 chiltk@acbs.com.vn

## **Company Update**

Recommendation	HOLD
	HSX: VNM

Consum	<b>Consumer staples</b>		
Target price (VND)	74,065		
Current price (VND)	77,500		
Expected share price return	-4.5%		
Expected dividend yield	5.0%		
Expected total return	0.5%		

#### Stock performance (%)

	YTD	1M	3M	12M
Absolute	1.8	-6.1	1.8	-0.9
Relative	-6.3	-3.5	-7.9	27.7



#### **Ownership**

36.0%
17.7%
10.6%

Stock Statistics	20-Feb-23
Bloomberg code	VNM VN
52-week range (VND)	64,500-85,600
Shares O/S (m)	2,090
Mkt cap (VND bn)	161,972
Mkt cap (USD m)	7,006
Foreign room left (%)	44.3
Est. free float (m)	35.1
3m avg daily vol (shrs)	1,886,330
VND/USD	23,870
Index: VNIndex / HNX	1086.6/215.8

## **VIETNAM DAIRY PRODUCTS JSC (VNM VN)**

We project that VNM may continue to generate single-digit growth in 2023. Although profit margins are expected to improve thanks to milk material prices trending down, the improvements may be seen from 3Q23. We give a HOLD recommendation for the stock with a target price of VND74k/share, representing a 0.5% expected total return at the end of the year.

VNM announced net revenue of VND60,075bn (-1.6% YoY) and EAT of VND8,578bn (-19.3% YoY) in 2022. Domestic revenue fell by 1% YoY, including a 5.9% decline in 2Q22 which was explained by the company's rearrangement of distribution system, falling consumption volume as a result of an increase in selling prices, increasingly tougher competition and probable impacts from inflationary pressures on consumer spending structure. Overseas revenue dropped by 4.8% YoY in 2022; in which, revenue from overseas subsidiaries rose by 23.3% YoY while direct exports tumbled by 21.2% YoY, attributed to weaker consumption amid escalated inflation.

We expect VNM's revenue may return to growth in 2023 (assuming no increase in selling prices), driven by recovery of domestic revenue following rearrangement of distribution system and the company's plan to change/upgrade products in terms of flavor, packaging, quality standards, etc. However, a single-digit growth rate is still assumed, considering the company's stable growth stage and consumer purchasing power amid concerns about future income and job security due to unfavorable economic conditions.

2022 EAT slumped by 19.3% YoY driven by a narrower gross margin despite a lower SG&A expenses to net revenue ratio (23.6% vs. 23.8% in 2021). The gross margin squeezed to 39.9% from 43.1% in 2021 because of surging milk material prices from late 2021. However, as a reversal in milk material prices has been seen since 2H22, VNM estimates the gross margin may enhance from 3Q23, slower than our previous expectations. We expect the company's gross margin may reach 40.7% in 2023 and expand further next year.

In sum, our projections for VNM's net revenue and EAT are VND61,850bn (+3.2% YoY) and VND9,350bn (+9.0% YoY), respectively, in 2023. Combining the DCF and PER methods, our target price for this stock is VND74k/share.

	2021	2022U	2023F	2024F	2025F
Net Sales (VNDbn)	60,919	59,956	61,850	64,819	67,671
Growth	2.2%	-1.6%	3.2%	4.8%	4.4%
EBITDA (VNDbn )	13,879	11,578	12,567	14,667	15,312
EBITDA margin	22.8%	19.3%	20.3%	22.6%	22.6%
Net Profit (VNDbn )	10,533	8,516	9,293	10,989	11,524
Growth	-5.1%	-19.1%	9.1%	18.3%	4.9%
EPS (bonus-adjusted, VND)	4,531	3,664	3,999	4,729	4,959
Growth	-5.1%	-19.1%	9.1%	18.3%	4.9%
ROE	32.7%	27.1%	30.5%	33.7%	32.2%
ROA	20.7%	16.7%	18.9%	21.5%	21.7%
Net debt/EBITDA (times)	-1.0	-1.3	-1.2	-1.0	-1.1
EV/EBITDA (times)	10.6	12.7	11.7	10.0	9.6
EV/sales (times)	2.4	2.5	2.4	2.3	2.2
PER (times)	17.1	21.1	19.4	16.4	15.6
PBR (times)	4.9	5.4	5.2	4.8	4.3
DPS (VND)	3,850	3,850	3,850	3,850	3,850
Dividend yield	5.0%	5.0%	5.0%	5.0%	5.0%

#### **ACBS Research Department** Tel: (+84) (8) 7300 7000


www.acbs.com.vn Bloomberg: ACBS <GO>



## VNM Update- HOLD

### 21-Feb-23

VNM FINANCIALS MODEL	Price (VND):	77,500 Targ	get (VND): 7	4,065 Mkt caj (VND bn)	
(VND bn except where stated)	2021	2022U	2023F	2024F	2025F
Total Net Sales	60,919	59,956	61,850	64,819	67,671
Sales growth (%)	2.2%	-1.6%	3.2%	4.8%	4.4%
CoGS ex-dep'n	32,520	33,964	34,572	34,541	36,062
Selling expenses	12,951	12,548	12,945	13,890	14,501
G&A expenses	1,567	1,596	1,770	1,725	1,801
Financial revenues	111	181	118	121	123
Financial expenses	114	452	114	116	119
EBITDA	13,879	11,578	12,567	14,667	15,312
EBITDA margin (%)	22.8%	19.3%	20.3%	22.6%	22.6%
Depreciation	2,121	2,095	2,098	2,161	2,273
Operating profit	11,758	9,483	10,469	12,506	13,039
Operating profit margin (%)	19.3%	15.8%	16.9%	19.3%	19.3%
Other profits/losses	195	4	3	3	3
Profits/Losses from associates	(45)	(24)	(13)	(6)	(3)
Net interest expense	(1,015)	(1,033)	(986)	(1,037)	(1,169)
as % of avg net debt	7.8%	7.2%	6.7%	7.0%	7.3%
Interest cover (x)	-11.6	-9.2	-10.6	-12.1	-11.2
Тах	2,290	1,918	2,095	2,485	2,610
Effective tax rate (%)	17.9%	18.2%	18.3%	18.4%	18.4%
Minority interest	100	62	57	65	74
Attributable net profit	10,533	8,516	9,293	10,989	11,524
Cash earnings	12,654	10,612	11,391	13,151	13,796
Total number of shares	2,089,955,445	2,089,955,445	2,089,955,445	2,089,955,445	2,089,955,445
EPS (VND) (after treasury shares)	4,531	3,664	3,999	4,729	4,959
Bonus factor (x)	1.00	1.00	1.00	1.00	1.00
Adjusted EPS (VND)	4,531	3,664	3,999	4,729	4,959
EPS growth (%)	-5.1%	-19.1%	9.1%	18.3%	4.9%



**ACBS Research Department** Tel: (+84) (8) 7300 7000


## VNM Update- HOLD

# ACBS

## 21-Feb-23

<b>KEY CASHFLOW AND BS ITEMS</b>	2021	2022U	2023F	2024F	2025F
Increase in working capital	1,713	-3,712	26	126	-23
Сарех	1,397	1,320	1,320	1,320	1,320
Change in investment in affiliates	-25	3	-28	-22	-18
Other cashflow items	-271	-4,090	-2,180	-3,135	-2,658
Free cash flow	9,299	8,911	7,894	8,591	9,860
Share issues	-	-	-	-	-
Dividends paid	7,524	8,046	8,046	8,046	8,046
Increase in net debt	-1,775	-865	153	-545	-1,814
Net debt, end of year	-13,916	-14,780	-14,628	-15,173	-16,987
Shareholders' equity	33,083	29,849	31,096	34,039	37,516
BVPS (VND)	15,830	14,282	14,879	16,287	17,951
Net debt / equity (%)	-42.1%	-49.5%	-47.0%	-44.6%	-45.3%
Net debt / EBITDA (x)	-1.0	-1.3	-1.2	-1.0	-1.1
Total assets	53,332	48,483	49,882	52,280	53,943

KEY RETURN AND VALUATION RATIOS	2021	2022U	2023F	2024F	2025F
ROE	32.7%	27.1%	30.5%	33.7%	32.2%
ROA	20.7%	16.7%	18.9%	21.5%	21.7%
ROIC	50.7%	44.9%	53.9%	57.5%	53.8%
WACC	11.7%	11.7%	11.7%	11.7%	11.7%
EVA	39.0%	33.2%	42.2%	45.8%	42.0%
PER (x)	17.1	21.1	19.4	16.4	15.6
EV/EBITDA (x)	10.6	12.7	11.7	10.0	9.6
EV/FCF (x)	15.8	16.5	18.6	17.1	14.9
PBR (x)	4.9	5.4	5.2	4.8	4.3
PSR (x)	2.7	2.7	2.6	2.5	2.4
EV/sales (x)	2.4	2.5	2.4	2.3	2.2
PEG (x, 3 yr prospective)	-3.4	7.7	1.8	1.8	3.2
Dividend yield	5.0%	5.0%	5.0%	5.0%	5.0%



### **ACBS Research Department** Tel: (+84) (8) 7300 7000



## VNM Update- HOLD 21-Feb-23

## CONTACTS

## Ho Chi Minh City Head Office

117 Nguyen Dinh Chieu, Dist. 3, Ho Chi Minh City Tel: (+84 28) 7300 7000 Fax: (+84 28) 7300 3751

## **RESEARCH DEPARTMENT**

## Hanoi Office

10 Phan Chu Trinh, Hoan Kiem Dist., Ha Noi Tel: (+84 4) 3942 9395 Fax: (+84 4)3942 9407

#### Associate Director Giao Nguyen (+84 28) 7300 7000 (x1041)

(+84 28) 7300 7000 (x1041) giaonbt@acbs.com.vn

Manager – Properties Truc Pham (+84 28) 7300 7000 (x1043) trucptt@acbs.com.vn Manager – Financials Hung Cao (+84 28) 7300 7000 (x1049) hungcv@acbs.com.vn Associate – Derivatives, Macro Minh Trinh Viet (+84 28) 7300 7000 (x1046) minhtvh@acbs.com.vn

Associate – Oil & Gas Hung Phan (+84 28) 7300 7000 (x1044) hungpv@acbs.com.vn

(+84 28) 7300 7000 (x1052)

Analyst – Technical

huuvp@acbs.com.vn

Huu Vo

Associate – Macro Hoa Nguyen (+84 28) 7300 7000 (x1050) hoant@acbs.com.vn

Associate – Industrials Huy Huynh (+84 28) 7300 7000 (x1048) huyha@acbs.com.vn

Associate – Consumer-related, Technology Chi Luong (+84 28) 7300 7000 (x1042) chiltk@acbs.com.vn Associate – Consumer-related, Technology Trung Tran (+84 28) 7300 7000 (x1045) trungtn@acbs.com.vn

Associate – Energy Toan Pham (+84 28) 7300 7000 (x1051) toanpd@acbs.com.vn Associate – Technical Phuoc Luong (+84 28) 7300 7000 (x1047) phuocld@acbs.com.vn

## **INSTITUTIONAL CLIENT DIVISION**

#### Director Huong Chu (+84 28) 7300 7000 (x1083) huongctk@acbs.com.vn

Customer Support Institutional Client Thanh Le (+84 28) 7300 7000 (x1089) thanhInt@acbs.com.vn

**Trader Thanh Tran** (+84 28) 7300 7000 (x1085) <u>thanhtt@acbs.com.vn</u> Trader Thao Nguyen (+84 28) 7300 7000 (x1087) thaont@acbs.com.vn Trader Huynh Nguyen (+84 28) 7300 7000 (x1088) huynhntn@acbs.com.vn

**Trader Dung Ly** (+84 28) 7300 7000 (x1084) <u>dungln.hso@acbs.com.vn</u> **Trader Nhi Nguyen** (+84 28) 7300 7000 (x1086) nhinp@acbs.com.vn

**ACBS Research Department** Tel: (+84) (8) 7300 7000 www.acbs.com.vn Bloomberg: ACBS <GO>



## DISCLAIMER

## **Our Recommendation System**

BUY:where we believe prospective 12 month VND total return (including dividends) will be 15% or more.

HOLD: where we believe it will be -15% to 15%.

**SELL:**where we believe it will be lower than -15%.

## Analyst Certification(s)

We, the author(s) of this report, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

## **Important Disclosures**

ACBS and/or an affiliate thereof (hereby collectively called ACBS) did or may seek to do business with companies covered in this report as its routine business. ACBS's proprietary trading accounts may have a position in such companies' securities. As a result, the investor should be aware that ACBS may have a conflict of interest from time to time.

ACBS produces a variety of research products including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research products, whether as a result of differing time horizons, methodologies, or otherwise.

## Disclaimer

This report is provided for information purposes only. ACBS makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this report. ACBS will not treat unauthorized recipients of this report as its clients. Prices shown (if any) are indicative and ACBS is not offering to buy or sell or soliciting offers to buy or sell any financial instrument. Without limiting any of the foregoing and to the extent permitted by law, in no event shall ACBS, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this report or its contents. Other than disclosures relating to ACBS, the information contained in this report has been obtained from sources that ACBS believes to be reliable, but ACBS does not represent or warrant that it is accurate or complete. The views in this report are subject to change, and ACBS has no obligation to update its opinions or the information in this report.

Some parts of this report reflect the assumptions, views and analytical methods of the analysts who prepared them, and ACBS is not responsible for any error of their works and assumptions. ACBS may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report.

The analyst recommendations in this report reflect solely and exclusively those of the author(s), and such opinions were prepared independently of any other interests, including those of ACBS. This report does not constitute personal investment advice or take into account the individual financial circumstances or objectives of the investors who receive it. The securities discussed herein may not be suitable for all investors. ACBS recommends that investors independently evaluate each issuer, securities or instrument discussed herein and consult any independent advisors they believe necessary. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results.

This report may not be distributed to the public media or used by the public media without prior written consent of ACBS. Otherwise it will be considered as illegal. The breacher shall compensate fully to ACBS any loss or damage which arises from such breach (if any). In the event that the distribution and/or receipt of this report is prohibited by the investor's jurisdiction, the investor shall dismiss this report immediately otherwise it will be at his/her own risks.

ACBS does not provide tax advice and nothing contained herein should be construed to be tax advice. Accordingly, the investors should seek advice based on their particular circumstances from an independent tax advisor. This report may contain links to third-party websites. ACBS is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this report and is not incorporated by reference into this report. The inclusion of a link in this report does not imply any endorsement by ACBS. Access to any third-party website is at the investor's own risks, and the investor should always review the terms and privacy policies at third-party websites before submitting any personal information to them. ACBS is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

© Copyright ACBS (2023).All rights reserved. No part of this report may be reproduced in any manner without the prior written permission of ACBS.

